North Crest Asset Manangement, LLC Halozyme Therapeutics, Inc. Transaction History
North Crest Asset Manangement, LLC
- $3.54 Billion
- Q2 2025
A detailed history of North Crest Asset Manangement, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, North Crest Asset Manangement, LLC holds 21,857 shares of HALO stock, worth $1.24 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
21,857
Previous 29,879
26.85%
Holding current value
$1.24 Million
Previous $1.91 Million
40.35%
% of portfolio
0.03%
Previous 0.06%
Shares
8 transactions
Others Institutions Holding HALO
# of Institutions
594Shares Held
124MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$997 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$726 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$342 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$220 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$208 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.88B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...